Impact of nanotechnology on drug delivery.

Nanotechnology is the engineering and manufacturing of materials at the atomic and molecular scale. In its strictest definition from the National Nanotechnology Initiative, nanotechnology refers to structures roughly in the 1-100 nm size regime in at least one dimension. Despite this size restriction, nanotechnology commonly refers to structures that are up to several hundred nanometers in size and that are developed by top-down or bottom-up engineering of individual components. Herein, we focus on the application of nanotechnology to drug delivery and highlight several areas of opportunity where current and emerging nanotechnologies could enable entirely novel classes of therapeutics.

[1]  Jacques Barbet,et al.  Targeting to cells of fluorescent liposomes covalently coupled with monoclonal antibody or protein A , 1980, Nature.

[2]  Jayanth Panyam,et al.  Single-step surface functionalization of polymeric nanoparticles for targeted drug delivery. , 2009, Biomaterials.

[3]  M. Yatvin,et al.  pH-sensitive liposomes: possible clinical implications. , 1980, Science.

[4]  Na Zhang,et al.  PLGA nanoparticle--peptide conjugate effectively targets intercellular cell-adhesion molecule-1. , 2008, Bioconjugate chemistry.

[5]  Robert Langer,et al.  Small-scale systems for in vivo drug delivery , 2003, Nature Biotechnology.

[6]  Robert Langer,et al.  Nanoparticle–aptamer bioconjugates for cancer targeting , 2006, Expert opinion on drug delivery.

[7]  T M Allen,et al.  Large unilamellar liposomes with low uptake into the reticuloendothelial system , 1987, FEBS letters.

[8]  M. Ferrari.  Cancer nanotechnology: opportunities and challenges , 2005, Nature Reviews Cancer.

[9]  A. Bangham,et al.  Diffusion of univalent ions across the lamellae of swollen phospholipids. , 1965, Journal of molecular biology.

[10]  Mauro Ferrari,et al.  Intravascular Delivery of Particulate Systems: Does Geometry Really Matter? , 2008, Pharmaceutical Research.

[11]  V. Torchilin,et al.  Biodegradable long-circulating polymeric nanospheres. , 1994, Science.

[12]  H. Maeda,et al.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.

[13]  Byeong-Su Kim,et al.  Hydrogen-bonding layer-by-layer-assembled biodegradable polymeric micelles as drug delivery vehicles from surfaces. , 2008, ACS nano.

[14]  Kazuo Maruyama,et al.  Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes , 1990, FEBS letters.

[15]  R Langer,et al.  New methods of drug delivery. , 1990, Science.

[16]  Jianjun Cheng,et al.  Targeted delivery of RNA-cleaving DNA enzyme (DNAzyme) to tumor tissue by transferrin-modified, cyclodextrin-based particles , 2004, Cancer biology & therapy.

[17]  Francesco Stellacci,et al.  Surface-structure-regulated cell-membrane penetration by monolayer-protected nanoparticles. , 2008, Nature materials.

[18]  Theresa M. Allen,et al.  Antitumor activity of an epithelial cell adhesion molecule–targeted nanovesicular drug delivery system , 2007, Molecular Cancer Therapeutics.

[19]  Eric Pridgen,et al.  Factors Affecting the Clearance and Biodistribution of Polymeric Nanoparticles , 2008, Molecular pharmaceutics.

[20]  U. Nielsen,et al.  Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. , 2006, Cancer research.

[21]  L. Zhang,et al.  Nanoparticles in Medicine: Therapeutic Applications and Developments , 2008, Clinical pharmacology and therapeutics.

[22]  R. Langer,et al.  Polymers for the sustained release of proteins and other macromolecules , 1976, Nature.

[23]  Volker Wagner,et al.  The emerging nanomedicine landscape , 2006, Nature Biotechnology.

[24]  J. Richie,et al.  Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[25]  R. Jain,et al.  Delivery of molecular and cellular medicine to solid tumors. , 1998, Journal of controlled release : official journal of the Controlled Release Society.

[26]  G. Whitesides.  The 'right' size in nanobiotechnology , 2003, Nature Biotechnology.

[27]  Stephanie E. A. Gratton,et al.  The effect of particle design on cellular internalization pathways , 2008, Proceedings of the National Academy of Sciences.

[28]  A. Ziegler.  Antibody Targeting of Liposomes : Cell Specificity Obtained by Conjugation of F ( ab ' ) 2 to Vesicle Surface , 2011 .

[29]  R. Langer,et al.  Drug delivery and targeting. , 1998, Nature.

[30]  M. Dewhirst,et al.  Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. , 2006, Journal of the National Cancer Institute.

[31]  Esther H Chang,et al.  Does a targeting ligand influence nanoparticle tumor localization or uptake? , 2008, Trends in biotechnology.

[32]  Michael L Simpson,et al.  Inducible RNA interference-mediated gene silencing using nanostructured gene delivery arrays. , 2008, ACS nano.

[33]  Gregory Glass,et al.  Pharmaceutical patent challenges — time for reassessment? , 2004, Nature Reviews Drug Discovery.

[34]  Jeffrey I. Zink,et al.  Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery , 2010, BiOS.

[35]  L. Robert,et al.  By the right. , 1988, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[36]  Robert Langer,et al.  Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers , 2008, Proceedings of the National Academy of Sciences.

[37]  Sai T Reddy,et al.  Exploiting lymphatic transport and complement activation in nanoparticle vaccines , 2007, Nature Biotechnology.